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Introduction
Prostate cancer (PCa) is the second most 
common noncutaneous cancer among men 
worldwide and the leading noncutaneous 
cancer among men in developed countries 
(Center et al. 2012). Little is known about 
the risk factors associated with this cancer: 
Advancing age, ethnic origins, and a family 
history of PCa are the only established risk 
factors (Damber and Aus 2008; Hsing and 
Chokkalingam 2006). Many lifestyle-related 
risk factors, including westernization of eating 
habits and environmental chemical pollution, 
have been implicated, but their true roles in the 
etiology of PCa remain unclear (Damber and 
Aus 2008; Hsing and Chokkalingam 2006).
The effects of exposure to synthetic 
chemicals with hormonal properties in the 
environment, also called endocrine disruptors 
(EDCs), on prostate cancer development are 
also matters of debate (Diamanti-Kandarakis 
et al. 2009; Prins 2008; World Health 
Organization 2013). Models of PCa are not 
available for regulatory testing. This makes the 
identification of prostatic hormonal carcino-
gens very difficult, and forces researchers to 
rely on epidemiological studies. However, 
epidemiological evidence remains limited 
(Soto and Sonnenschein 2010).
Persistent organic pollutants, including 
p,p´-dichlorodiphenyldichloroethylene 
(DDE, the major and most stable metabolite 
of dichlorodiphenyltrichloroethane, DDT) 
and polychlorinated biphenyls (PCBs), have 
attracted attention because of their wide-
spread presence both in the environment and 
in human beings, and their ability to interfere 
with hormone-regulated processes (Kelce 
et al. 1995; Plísková et al. 2005). Several 
epidemiological studies have investigated rela-
tionships between human exposure to DDE 
and PCBs, determined by blood measure-
ment, and PCa, but most of them found no 
association (Aronson et al. 2010; Ritchie et al. 
2003, 2005; Sawada et al. 2010). One study 
in the United States that included 65 PCa 
cases and 1,920 noncases reported a positive 
but not significant association with prevalent 
prostate cancer risk (Xu et al. 2010).
In a population-based case–control study 
of incident PCa patients and control subjects 
in the general population in Guadeloupe 
(French West Indies), environmental exposure 
to the estrogenic insecticide chlordecone was 
positively associated with PCa (Multigner 
et al. 2010). Here we report continuation of 
this study with a more detailed investigation 
of associations of DDE and PCBs with PCa.
Methods
Study population. This study took place 
in Guadeloupe (French West Indies), a 
Caribbean archipelago, where most of the 
inhabitants are of African descent. The study 
included 709 consecutive incident cases 
of histologically confirmed PCa and 723 
controls without PCa. Details of the selec-
tion of cases and controls have been described 
elsewhere (Multigner et al. 2010). Briefly, 
cases were recruited among subjects attending 
public and private urology clinics, with a 
recruitment area covering the entire territory 
of the Guadeloupe Archipelago. Controls 
were recruited from men participating in 
a free systematic health screening program 
open to the general population: Each year, 
a random population sample selected in 
accordance with the sex and age distribu-
tion of the general population was invited 
to participate in the program. Consecutive 
men ≥ 45 years of age were then invited to 
participate as controls in our case–control 
study of PCa, with selection according to 
the approximate age distribution of PCa 
diagnosis in Guadeloupe. Inclusion criteria 
for both cases and controls were current 
residence in Guadeloupe, both parents born 
on any Caribbean island with a population 
of predominantly African descent, and no 
hormone treatments or use of any other 
drugs known to influence the hypothalamic–
pituitary–gonadal–adrenal axis (including 
inhibitors of 5α-reductase). Additional 
inclusion criteria for controls were normal 
findings upon digital rectal examination and 
total plasma PSA (prostate-specific antigen) 
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Background: Long-term exposure to persistent pollutants with hormonal properties (endocrine-
disrupting chemicals; EDCs) may contribute to the risk of prostate cancer (PCa). However, 
epidemiological evidence remains limited.
oBjectives: We investigated the relationship between PCa and plasma concentrations of 
 universally widespread pollutants, in particular p,p´-dichlorodiphenyl dichloroethene (DDE) and 
the non-dioxin-like polychlorinated biphenyl congener 153 (PCB-153).
Methods: We evaluated 576 men with newly diagnosed PCa (before treatment) and 655 controls 
in Guadeloupe (French West Indies). Exposure was analyzed according to case–control status. 
Associations were assessed by unconditional logistic regression analysis, controlling for confounding 
factors. Missing data were handled by multiple imputation. 
results: We estimated a significant positive association between DDE and PCa [adjusted odds 
ratio (OR) = 1.53; 95% CI: 1.02, 2.30 for the highest vs. lowest quintile of exposure; ptrend = 0.01]. 
PCB-153 was inversely associated with PCa (OR = 0.30; 95% CI: 0.19, 0.47 for the highest vs. 
lowest quintile of exposure values; ptrend < 0.001). Also, PCB-153 was more strongly associated with 
low-grade than with high-grade PCa.
conclusions: Associations of PCa with DDE and PCB-153 were in opposite directions. This may 
reflect differences in the mechanisms of action of these EDCs; and although our findings need to be 
replicated in other populations, they are consistent with complex effects of EDCs on human health.
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concentration no higher than the 75th 
percentile for the corresponding age group 
of African-American men without clinical 
evidence of PCa (Morgan et al. 1996). 
Trained nurses obtained information for 
both patients and controls. Case patients were 
interviewed within 2 months of diagnosis, 
before receiving any kind of treatment. 
All subjects were interviewed in person to 
obtain information about their age (years), 
Caribbean origin (French West Indies, Haiti, 
or Dominica), education (primary, secondary, 
high school and higher), weight and height 
allowing the calculation of body mass index 
(BMI; kilograms per meter squared), waist 
and hip circumference allowing the calcula-
tion of waist-to-hip ratio (≤ 0.95, > 0.95), 
smoking (never, former, or current), alcohol 
consumption (never, former, or current), 
diabetes type 2 (no, yes), past residence in 
Western countries (no, yes), history of PSA 
screening (within the preceding 5 years: no, 
yes), and family history of PCa (first degree 
relatives: no, yes, not known). Participants 
were also asked to provide a blood sample 
between 0800 and 1000 hours, after over-
night fasting. The study was approved by the 
Guadeloupean ethics committee for studies 
involving human subjects. Each participant 
provided written informed consent.
Laboratory assays. A high-resolution gas 
chromatograph (Thermo Quest Trace 2000, 
Milan, Italy) equipped with a Ni63 electron 
capture detection system was used to deter-
mine the serum concentrations of 24 PCB 
congeners (International Union of Pure and 
Applied Chemistry number): 6 dioxin-like 
(77, 105, 118, 126, 156, and 169) and 18 
non-dioxin-like (18, 28, 52, 101, 110, 128, 
138, 143, 149, 153, 170, 180, 183, 187, 194, 
195, 206, and 209); p,p´-DDT, p,p´-DDD 
(dichlorodiphenyldichloroethane), and 
p,p´-DDE; the α, β, and γ isomers of hexa-
chlorocyclohexane (HCH); and chlordecone. 
The limit of detection (LOD) was 0.05 μg/L 
for all organochlorine compounds except for 
chlordecone (0.06 μg/L). Detailed informa-
tion about sampling, analysis, and quality 
assurance and control has been provided else-
where (Debier et al. 2003; Multigner et al. 
2010). Plasma total cholesterol and total 
triglyceride concentrations were determined 
enzymatically (DiaSys Diagnostic Systems 
GmbH, Holzheim, Germany), and total lipid 
concentration was calculated as previously 
described (Bernert et al. 2007).
Statistical analysis. We restricted our 
analysis to chemicals detected at a rate of 
more than 80% (DDE; PCB congeners 138, 
153, and 180; and chlordecone) (Table 1). 
Correlations between concentrations of the 
frequently detected pollutants were explored 
by Spearman’s rank correlation analysis 
(see Supplemental Material, Table S1). The 
concentrations of the various PCBs were 
highly correlated (Spearman’s rho ≥ 0.76; 
all p-values < 0.001), so we restricted further 
analysis to PCB-153.
The odds ratio (OR) and 95% confi-
dence intervals (CIs) for the association 
between PCa and organochlorines according 
to category of exposure were estimated 
using unconditional logistic regression. 
Organochlorines were categorized into 
quintiles according to the distribution in 
control subjects. Exposure levels equal to or 
below the LOD were included in the first 
(lowest) quintile.
Potential confounders were included 
as covariates in logistic models if they 
predicted case status (Table 2) and exposure 
(see Supplemental Material, Table S2) 
with p < 0.05. We also adjusted all models 
for total lipids (grams per liter), rather than 
modeling concentrations of the fat-soluble 
exposure of interest on a per-unit serum-
lipid basis, because the latter approach may 
be prone to bias (Porta et al. 2009). For 
each exposure, we also considered the other 
contaminants as potential confounders. 
Spearman’s rank correlation coefficients 
between chlordecone and DDE concentra-
tions and between chlordecone and PCB-153 
concentrations were low (ρ = 0.05 and 0.07 
in controls, and 0.04 and 0.07 in cases, respec-
tively; see Supplemental Material, Table S1). 
Consequently,  chlordecone was not considered 
as a confounder. 
Next, models of DDE as the primary 
exposure were adjusted for age (log linearity 
of age was not achieved, so age was categorized 
as quartiles according to the age distribution 
of the controls), waist-to-hip ratio, type 2 
diabetes, alcohol consumption, total lipids, 
and PCB-153 (quintiles). Models of PCB-153 
as the exposure were adjusted for the same 
covariates, plus Caribbean origin and past 
residence in a Western country, and DDE 
(quintiles). Sensitivity analyses were conducted 
including additional adjustment for BMI, 
PSA screening history, family history of 
PCa, and chlordecone. Additional sensitivity 
analyses were realized excluding any subject 
(n = 199), control or case, with a prediagnostic 
BMI < 18.5 or > 30.
Missing data for covariates varied from 
none to 2 (0.2%) for past residence in 
Western countries and for PSA screening 
history, 8 (0.6%) for smoking, 20 (1.6%) 
for alcohol, 27 (2.2%) for family history of 
PCa, 30 (2.4%) for education, 34 (2.8%) 
for diabetes, 37 (3.0%) for BMI, and 219 
(17.8%) for waist-to-hip ratio. Missing 
data were handled by multiple imputations 
Table 1. Detection and concentrations of organochlorine pollutants in plasma samples from the study 





Maximum10th 25th 50th 75th
Controls
p,p ´-DDT 36.2 < LOD < LOD < LOD 0.07 (0.01) 1.7 (0.32)
p,p ´-DDD 24.0 < LOD < LOD < LOD 0.04 (0.008) 0.84 (0.15)
p,p ´-DDE 96.2 0.39 (0.07) 0.98 (0.18) 2.06 (0.38) 4.37 (0.75) 27.8 (6.7)
PCB-28 54.5 < LOD < LOD 0.07 (0.01) 0.28 (0.05) 8.0 (1.4)
PCB-52 42.6 < LOD < LOD < LOD 0.28 (0.05) 12.7 (2.5)
PCB-101 52.1 < LOD < LOD 0.05 (0.009) 0.13 (0.02) 1.1 (0.21)
PCB-118 59.2 < LOD < LOD 0.08 (0.01) 0.20 (0.03) 3.3 (0.9)
PCB-138 97.4 0.18 (0.03) 0.31 (0.06) 0.53 (0.10) 0.90 (0.16) 12.2 (2.4)
PCB-153 98.2 0.24 (0.05) 0.48 (0.09) 0.85 (0.15) 1.47 (0.26) 16.5 (3.5)
PCB-180 97.4 0.23 (0.04) 0.39 (0.07) 0.64 (0.12) 1.03 (0.18) 10.3 (2.0)
α-HCH 35.9 < LOD < LOD < LOD 0.08 (0.01) 1.6 (0.32)
β-HCH 43.5 < LOD < LOD < LOD 0.09 (0.02) 1.9 (0.30)
γ-HCH 27.7 < LOD < LOD < LOD 0.08 (0.01) 1.8 (0.41)
Chlordecone 84.1 < LOD 0.17 (0.03) 0.42 (0.08) 0.83 (0.15) 49.2 (8.8)
Cases
p,p ´-DDT 29.3 < LOD < LOD < LOD 0.06 (0.01) 2.5 (0.43)
p,p ´-DDD 20.1 < LOD < LOD < LOD 0.03 (0.006) 0.99 (0.15)
p,p ´-DDE 95.5 0.40 (0.08) 1.11 (0.22) 2.55 (0.50) 5.74 (1.07) 40.1 (6.6)
PCB-28 52.6 < LOD < LOD 0.06 (0.01) 0.29 (0.05) 6.8 (1.1)
PCB-52 49.3 < LOD < LOD < LOD 0.38 (0.07) 6.7 (1.1)
PCB-101 51.2 < LOD < LOD 0.05 (0.009) 0.13 (0.02) 1.2 (0.17)
PCB-118 62.0 < LOD < LOD 0.08 (0.02) 0.18 (0.03) 2.4 (0.52)
PCB-138 97.9 0.17 (0.03) 0.30 (0.06) 0.54 (0.10) 0.87 (0.18) 6.7 (1.1)
PCB-153 98.8 0.23 (0.04) 0.41 (0.06) 0.78 (0.10) 1.24 (0.18) 8.4 (1.3)
PCB-180 97.2 0.25 (0.05) 0.37 (0.07) 0.62 (0.12) 0.90 (0.18) 6.2 (1.0)
α-HCH 28.5 < LOD < LOD < LOD 0.05 (0.01) 1.2 (0.20)
β-HCH 38.0 < LOD < LOD < LOD 0.11 (0.02) 2.2 (0.46)
γ-HCH 18.4 < LOD < LOD < LOD < LOD 0.65 (0.13)
Chlordecone 82.8 < LOD 0.18 (0.03) 0.43 (0.08) 0.94 (0.18) 26.4 (4.1)
aPCB congeners 18, 77, 101, 105, 110, 126, 128, 143, 149, 156, 169, 170, 183, 187, 194, 195, 206, and 209 were below the LOD 
in all cases and controls.
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according to the methodology described 
by Rubin (1987) and Little and Rubin 
(1987) using chained equations (MICE; 
multiple imputation by chained equations) 
(Van Buuren et al. 1999; White et al. 2009). 
For the imputation procedure, we included 
the following characteristics: age, Caribbean 
origin, education, weight, height, waist and 
hip circumference, smoking, alcohol, diabetes, 
PSA screening history, family history of PCa, 
past residence in Western countries, total 
plasma lipids, all organochlorines, and case–
control status. Five imputed data sets were 
generated using 20 cycles per imputation, 
and the main analyses were repeated using 
the imputed data. In addition, we performed 
sensitivity analyses substituting missing data 
with a missing value indicator variable, and 
by using complete case analyses restricted to 
participants with known values of all covari-
ates. Tests for trends were performed by 
modeling categorical exposures as ordinal 
variables after assigning median values to each 
exposure category.
We considered possible interactions 
between organochlorine exposure and covari-
ates in relation to PCa. The cross-product of 
covariates (BMI < 25 or > 25 kg/m2; waist-
to-hip ratio ≤ 0.95 or > 0.95; smoking, never 
versus former or current; alcohol consump-
tion, never versus former or current; diabetes 
type 2, yes, no; past residence in Western 
countries, yes, no; history of PSA screening, 
yes, no) and exposures (quintiles) was intro-
duced in the logistic model. Subjects with 
missing values for the factors of interest were 
excluded from these analyses. We adjusted 
for the same covariates as the main model for 
each exposure. Consistent with the recom-
mendations of Seaman et al. (2012), these 
analyses were restricted to participants with 
known values of all covariates. The p-value for 
interaction was calculated by the likelihood 
ratio test comparing the log-likelihood for the 
model with the interaction terms to the log-
likelihood for the model without the inter-
action term. Interactions with a p-value for 
the cross-term product ≤ 0.20 were further 
assessed with stratified analyses.
Polytomous logistic regressions models 
were used to estimate associations between 
exposures and case subgroups (versus controls) 
according to grade (low grade: Gleason score 
< 7 or 3 + 4; high grade: Gleason score 4 + 3 
or > 7) and clinical stage at diagnosis (tumor, 
nodes, metastases; localized stage: T1c or T2 
and N0 and M0; advanced stage: T3 or T4, or 
N+ or M+). Exposures were categorized into 
tertiles according to the distribution in control 
subjects for theses analyses.
Us ing  prev ious ly  publ i shed data 
(Multigner et al. 2010), we reanalyzed the 
association between chlordecone exposure 
and PCa among participants included in 
the present analysis, with additional adjust-
ment for plasma DDE and PCB-153. After 
analysis of quality control samples consisting 
of human plasma spiked with a series of 
concentrations of chlordecone, we defined 
the LOD for plasma chlordecone concen-
trations as 0.06 μg/L, rather than using an 
LOD of 0.25 μg/L, as in our previous analysis 
(Multigner et al. 2010).
SAS software version 9.3 (SAS Institute 
Inc., Cary, NC, USA) was used for analyses; 
all tests were two-sided, and p-values < 0.05 
were considered statistically significant.
Results
The results presented here were obtained from 
a study population comprising 576 of the 
709 eligible PCa cases and 655 of the eligible 
722 controls, from whom we were able to 
obtain blood samples and measure plasma 
organochlorine concentrations. The baseline 
characteristics of the study population are 
summarized in Table 2.
The adjusted OR was 1.53 (95% CI: 
1.02, 2.30) for men in the highest quintile of 
DDE concentration compared with men in 
the lowest quintile (Table 3). The relationship 






Age (years) [mean (range)] 65.9 (52.6–79.1) 60.9 (48.0–77.1) < 0.001
Caribbean origin 
French West Indies 556 (96.5) 598 (91.3) < 0.001
Haiti or Dominica 20 (3.5) 57 (8.7)
Education 
Primary 349 (61.0) 362 (57.5) 0.04
Secondary 147 (25.7) 201 (32.0)
High school and higher 76 (13.3) 66 (10.5)
Missing data 4 26
Body mass index (kg/m2) 
< 25 241 (44.5) 306 (46.9) 0.54
25 to < 30 240 (44.3) 268 (41.1)
≥ 30 61 (11.2) 78 (12.0)
Missing data 34 3
Waist-to-hip ratio 
≤ 0.95 196 (54.4) 455 (69.8) < 0.001
> 0.95 164 (45.6) 197 (30.2)
Missing data 216 3
Smoking 
Never 355 (62.2) 410 (62.9) 0.80
Former or current 216 (37.8) 242 (37.1)
Missing data 5 3
Alcohol consumption 
Never 74 (13.0) 112 (17.4) 0.03
Former or current 494 (87.0) 536 (82.6)
Missing data 8 12
Type 2 diabetes 
No 457 (81.5) 556 (87.4) 0.004
Yes 104 (18.5) 80 (12.6)
Missing data 15 19
Past residence in Western countries
No 403 (70.0) 498 (76.3) 0.01
Yes 173 (30.0) 155 (23.7)
Missing data — 2
PSA screening history
No 278 (48.4) 572 (87.3) < 0.001
Yes 296 (51.6) 83 (12.7)
Missing data 2 —
Family history of prostate cancer
No 317 (55.9) 498 (78.2) < 0.001
Yes 144 (25.4) 66 (10.4)
Do not know 106 (18.6) 74 (11.4)
Missing data 9 18
Gleason score 
< 7 or 3 + 4 462 (82.1) —
> 7 or 4 + 3 101(17.9) —
Missing data 9
Clinical stage (T, N, M) 
T1c or T2 and N0 and M0 485 (87.4) —
T3 or T4, or N+ or M+  70 (12.6) —
Missing data 21
ap-Values were calculated using a two-sided chi-square test for a comparison of percentages or by a two-sided Student 
t-test for a comparison of means.
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between exposure and PCa was significant 
(ptrend = 0.01). This overall trend seems to 
be mainly driven by the OR for the highest 
versus lowest quintiles, because the other 
ORs were close to null. Results of sensitivity 
analyses were comparable with the primary 
analysis when missing data were modeled 
using missing value indicator categories; when 
we performed complete case analyses; and 
when BMI, PSA screening history, family 
history of PCa, or chlordecone exposure were 
included in the full model (see Supplemental 
Material, Table S3). Excluding subjects 
with BMI < 18.5 and > 30 resulted in a 
slight decrease in the OR (1.43; 95% CI: 
0.93, 2.20), but the trend across exposure 
categories remained significant (ptrend = 0.04) 
(see Supplemental Material, Table S3).
Contrary to what was observed for DDE, 
adjusted ORs relative to the lowest quintile of 
PCB-153 concentration all were significantly 
below 1 (OR = 0.30; 95% CI: 0.19, 0.47 for 
the highest versus lowest quintile) (Table 3). 
The overall trend for the association across 
exposure categories was significant (ptrend 
< 0.001). In sensitivity analyses, associa-
tions were comparable when missing data 
were modeled using missing value indicator 
categories; when restricted to a complete 
case analysis; and when additionally adjusted 
for BMI, PSA screening history, family 
history of PCa, or chlordecone exposure (see 
Supplemental Material, Table S4). Also, 
exclusion of subjects with BMI < 18.5 and 
> 30 did not greatly affect the ORs (see 
Supplemental Material, Table S4).
We did not find any evidence of effect 
modification (interaction p-values > 0.2, data 
not shown) except for family history of PCa 
and PCB-153 exposure (see Supplemental 
Material, Table S5). Associations between 
PCB-153 exposure and PCa were stronger in 
men without a family history of PCa, and the 
interaction terms, although not significant, 
were < 0.10 for the three highest quintiles 
of exposure.
Our next analyses considered clinical char-
acteristics. The adjusted OR for cases with 
high-grade Gleason score was 1.92 (95% CI: 
1.04, 3.54) for men in the highest tertile 
relative to men in the lowest tertile of DDE 
concentration (Table 4), but this was not 
significantly different from the corresponding 
OR value for cases with low-grade Gleason 
score (pheterogeneity = 0.13). For PCB-153, a 
significant inverse association was observed 
among cases with low-grade Gleason score 
(OR = 0.35; 95% CI: 0.25, 0.51) for men 
in the highest tertile relative to men in the 
lowest tertile (Table 4); this was significantly 
different from what was observed for cases 
with high-grade score (pheterogeneity = 0.04). No 
significant differences were observed between 
localized and advanced stage of PCa for either 
DDE or PCB-153 exposure.
Finally, we reanalyzed the association 
between chlordecone exposure and PCa: 
the OR was 1.65 (95% CI: 1.09, 2.48; 
ptrend = 0.01) for men in the highest quintile 
compared with men in the lowest quintile 
(see Supplemental Material, Table S6). 
Comparable results were observed if DDE or 
PCB-153 concentrations were included in the 
full model (OR = 1.64; 95% CI: 1.09, 2.47; 
ptrend = 0.01, and OR = 1.70; 95% CI: 
1.12, 2.56; ptrend = 0.008, respectively) (see 
Supplemental Material, Table S6).
Discussion
In our study population, the highest quintile 
of exposure to DDE, evaluated by deter-
mining plasma p,p´-DDE concentrations, 
was positively associated with incident PCa. 
By contrast, plasma PCB-153 was inversely 
associated with PCa, with significant negative 
associations for all quintiles above the refer-
ence level, and the strongest association with 
the highest quintile.
These results were obtained by studying 
a population with plasma concentrations 
consistent with the range of background 
environmental levels currently found in 
U.S. populations of similar age (Centers for 
Disease Control and Prevention 2009). The 
median value for plasma lipid–adjusted DDE 
(0.38 μg/g) and PCB-153 (0.15 μg/g) in our 
control population was, for DDE, in the same 
range as (0.27–0.94 μg/g) and, for PCB-153, 
slightly higher (0.04–0.09 μg/g) than those in 
control populations in other studies investi-
gating the relationships between these pollut-
ants, determined by blood measurement, and 
PCa (Aronson et al. 2010; Ritchie et al. 2003, 
2005; Sawada et al. 2010; Xu et al. 2010). In 
the French West Indies, DDT has not been 
extensively used in agricultural supplies or 
Table 3. ORs (95% CIs) of prostate cancer according to quintile of DDE and PCB-153 exposure.
Exposure Controls (n) Cases (n) Crude OR (95% CI) Adjusted ORa (95% CI)
DDE (μg/L)
< 0.79 131 106 1.0 (reference) 1.0 (reference)
0.79–1.62 130 96 0.91 (0.63, 1.62) 0.96 (0.66, 1.42)
1.63–2.89 133 111 1.03 (0.72, 1.48) 1.05 (0.71, 1.55)
2.90–5.18 131 104 0.98 (0.68, 1.41) 1.02 (0.67, 1.53)
≥ 5.19 130 159 1.51 (1.07, 2.13) 1.53 (1.02, 2.30)
pTrend 0.003 0.01
PCB-153 (μg/L)
< 0.41 132 141 1.0 (reference) 1.0 (reference)
0.41–0.69 132 109 0.77 (0.55, 1.09) 0.56 (0.38, 0.83)
0.70–1.07 134 135 0.94 (0.67, 1.32) 0.67 (0.46, 0.99)
1.08–1.70 131 110 0.79 (0.55, 1.11) 0.45 (0.30, 0.63)
≥ 1.71 126 81 0.60 (0.42, 0.87) 0.30 (0.19, 0.47)
pTrend 0.01 < 0.001
aFor DDE: adjusted for age, waist-to-hip ratio, type 2 diabetes, alcohol, total plasma lipid concentration, and PCB-153. 
For PCB-153: adjusted for age, waist-to-hip ratio, Caribbean origin, past residence in Western countries, type 2 diabetes, 
total plasma lipid concentration, alcohol, and DDE. Missing values were imputed using a multiple imputation by chained 
equation (MICE) approach in five data sets.





















< 1.37 218 144 1.0 (reference) 20 1.0 (reference) 145 1.0 (reference) 15 1.0 (reference)
1.37–3.41 218 151 1.06 (0.77, 1.47) 34 1.55 (0.85, 2.85) 0.23 160 1.11 (0.81, 1.52) 23 1.44 (0.69, 2.98) 0.50
≥ 3.42 219 167 1.18 (0.84, 1.65) 47 1.92 (1.04, 3.54) 0.13 180 1.26 (0.91, 1.76) 32 1.39 (0.66, 2.93) 0.83
pTrend 0.33 0.06 0.18 0.55
PCB-153 (μg/L)
< 0.60 218 183 1.0 (reference) 28 1.0 (reference) 181 1.0 (reference) 22 1.0 (reference)
0.61–1.24 216 174 0.78 (0.57, 1.06) 39 1.11 (0.63, 1.95) 0.22 189 0.83 (0.61, 1.14) 23 0.84 (0.42, 1.68) 0.97
≥ 1.25 221 105 0.35 (0.25, 0.51) 34 0.69 (0.37, 1.29) 0.04 115 0.38 (0.27, 0.55) 25 0.64 (0.30, 1.35) 0.19
pTrend < 0.001 0.10 < 0.001 0.28
aFor DDE: adjusted for age, waist-to-hip ratio, alcohol, type 2 diabetes, total plasma lipid concentration, and PCB-153. For PCB-153: adjusted for age, waist-to-hip ratio, Caribbean 
origin, past residence in Western countries, type 2 diabetes, total plasma lipid concentration, alcohol, and DDE. Missing values were imputed using a multiple imputation by chained 
equation (MICE) approach in five data sets. bp-Value from the Wald test for heterogeneity of respective β coefficients between low-grade and high-grade prostate cancer. cp-Value 
from the Wald test for heterogeneity of respective β coefficients between localized and advanced-stage prostate cancer.
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for disease vector control. In addition, this 
territory has had only very limited industrial 
activities involving significant use or emission 
of PCBs. Consequently, exposure to these 
chemical pollutants is likely to be associ-
ated with background contamination of the 
food chain.
To our knowledge, this is the largest study 
to have investigated associations of DDE and 
PCBs with PCa based on biological measure-
ments of exposure. Other strengths of this 
study include its population-based design, the 
consideration of co-exposure to other organo-
chlorine compounds [particularly chlorde-
cone, which has been found previously to be 
associated with the risk of PCa (Multigner 
et al. 2010)], case evaluation and exposure 
measurement within 2 months of diagnosis 
and before treatment, and using multiple 
imputation to handle missing data.
Our study also suffers some limitations 
inherent in the case–control design. Factors 
potentially generating bias must be consid-
ered, particularly those relating to differen-
tial errors in the measurement of disease or 
exposure. Case identification was based on 
unambiguous histological criteria, and 
controls were also selected on the basis of strict 
criteria, such as normal findings on digital 
rectal examination and PSA in the normal 
range for age, taking into account the ethnic 
background of the population.
The use of DDT and PCBs spread world-
wide around the middle of the 20th century, 
so the study population has probably been 
exposed to these chemicals or their metabo-
lites throughout much of their lifetimes. 
Single determinations of plasma organo-
chlorine concentration provide an accurate 
reflection of the load of this compound in 
the body and are commonly used as an effec-
tive way to determine the extent of chronic 
exposure to these chemicals. However, ques-
tions have been raised about whether a single 
blood determination of persistent chemicals 
at the time of cancer diagnosis is a reliable 
indicator representing lifetime exposure, 
particularly for breast cancer (Verner et al. 
2011). Nevertheless, unlike women, men are 
not subject to the mobilization of fat-soluble 
chemicals during pregnancy or breastfeeding 
that can significantly alter the pollutant load 
of the whole body. Any previous weight loss 
or gain, particularly if substantial, may modify 
the blood concentration of these pollutants. 
Unfortunately, we did not collect data for 
our study population about the gain or loss of 
body weight during adulthood. To overcome, 
albeit only in part, this lack of information, we 
performed a sensitivity analysis by excluding 
subjects who were underweight or obese: 
These individuals were, perhaps, the most 
likely to have changed weight significantly 
since the beginning of adulthood.
Few studies have investigated relationships 
between human exposure to DDE and PCBs, 
determined by blood measurement, and PCa, 
but all were inconclusive (Aronson et al. 2010; 
Ritchie et al. 2003, 2005; Sawada et al. 2010; 
Xu et al. 2010). Nevertheless, Xu et al. (2010) 
reported that ORs for the second and third 
tertiles of DDE exposure were 2.05 (95% CI: 
0.76, 5.5) and 2.64 (95% CI: 0.92, 7.57), 
respectively. Nonsignificant inverse asso-
ciations have been reported between PCBs 
and PCa in a Canadian case–control study 
(Aronson et al. 2010) and in a Japanese nested 
case–control study specifically addressing 
advanced-stage PCa (Sawada et al. 2010). An 
ecological study in Eastern Slovakia reported 
a lower incidence of PCa in a district with 
extensive environmental contamination from 
a former PCB production site, where residents 
presented higher concentrations of PCBs in 
blood levels than in a district without any 
history of PCB production and where resi-
dents had low blood concentrations of PCBs 
(Pavuk et al. 2004).
We investigated whether exposure to 
DDE or PCB-153 was associated with PCa 
aggressiveness. Gleason score and clinical stage 
at diagnosis are powerful predictors of the 
aggressiveness of PCa. In particular, patients 
with high-grade Gleason scores have lower 
metastasis-free survival and higher PCa-specific 
mortality. PCB-153 exposure appeared to be 
negatively associated with low-grade Gleason 
score. Screening procedures may have intro-
duced distortions in the associations observed 
between exposures of interest and cancer 
outcomes if fewer cases had been included 
in the absence of screening (Weiss 2003). In 
our study population, the prevalence of PSA 
screening among PCa cases with low-grade 
Gleason score was 76.7% but among PCa 
cases with a high-grade score, it was only 
10%. Also, we found that additional adjust-
ment for PSA screening did not change the 
risk estimates (data not shown). These various 
observations suggest that PCB-153 exposure 
may truly decrease the occurrence of low-
grade PCa without changing the occurrence 
of high-grade forms. Koutros et al. (2013) 
have suggested that the different associations 
between chemical exposures (i.e., pesticides) 
and PCa aggressiveness may be consequences 
of different roles of such exposures in the 
prostatic carcinogenesis (for example, earlier 
initiation stage vs. prostate cancer progres-
sion). However, it has not been established that 
nonaggressive and aggressive forms of PCa are 
etiologically and pathogenically similar.
Finally, we found that the negative 
association between PCB-153 and PCa was 
stronger among subjects without a family 
history of PCa than among those with such a 
family history. Because the interaction terms 
were not strictly significant and number of 
cases with a family history of PCa was very 
small, these results should be interpreted 
with caution. This result differs from those 
reported for various other organochlorine or 
pesticide exposures: Increased risks have been 
observed among subjects with a family history 
of PCa, possibly due to genetic susceptibility 
(Alavanja et al. 2003; Christensen et al. 2010; 
Lynch et al. 2009; Mahajan et al. 2006; 
Multigner et al. 2010). Overall, exposure to 
PCB-153 appears to be inversely associated 
with less aggressive prostate cancer and tends 
to be most strongly associated among subjects 
without a family history of PCa; such patients 
have a better prognosis than those with a 
family history (Kupelian et al. 2006). 
Mainly on the basis of data from animal 
experiments, the International Agency for 
Research on Cancer (IARC) currently clas-
sifies DDT as “possibly carcinogenic to 
humans” and PCBs (because of their positive 
association with melanoma in humans) as 
“probably carcinogenic to humans” (IARC 
1991). Both are classified as “reasonably 
anticipated to be human carcinogens” by the 
National Toxicology Program (2014). Thus, 
the observation from this study that PCa is 
positively associated with DDE and nega-
tively associated with PCB-153 is unexpected; 
however, these findings may reflect differ-
ences in the hormonal properties of DDE 
and PCB-153 and their effects on prostate 
development, as discussed below.
DDE displays anti-androgenic effects 
in vivo, as assessed from changes in the 
weights of androgen-responsive tissues 
(Owens et al. 2007). These effects are probably 
mediated by competitive binding to the 
androgen receptor (AR) and/or inhibition of 
AR-dependent gene expression (Kelce et al. 
1995, 1997). In adult healthy subjects without 
PCa, DDE exposure is negatively associated 
with serum concentration of dihydrotestos-
terone (Emeville et al. 2013), suggesting that 
DDE could also indirectly affect androgen 
signaling. However, DDE, like many other 
EDCs, has mixed actions on different 
members of the steroid receptor superfamily. 
DDE also exerts agonistic activity on estrogen 
receptor alpha (ERα) (Li et al. 2008). ERα 
mediates adverse effects of estrogen on the 
prostate, including aberrant proliferation, 
inflammation, and malignancy (Ellem and 
Risbridger 2009). It is therefore difficult to 
predict the net effect of DDE on the prostate 
given potential effects on both AR and ERα 
(Carruba 2007; Ellem and Risbridger 2010).
Unlike dioxin-like PCBs, non-dioxin-like 
PCBs, which are the most common preva-
lent PCBs in the environment (McFarland 
and Clarke 1989), do not interact substan-
tially with the aryl hydrocarbon receptor and 
may act through different pathways, such as 
steroid hormone signaling (Cooke et al. 2001). 
Emeville et al.
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Experimental studies using various animal 
models have shown that PCB-153—the PCB 
congener most commonly found in animal and 
human tissues, due to its high persistence and 
low environmental degradability (Safe 1993)—
has pro-estrogenic activities (Cooke et al. 
2001; Dickerson et al. 2011; Hansen 1998). 
However, PCBs have also been reported to 
be anti-estrogenic in both reporter gene and 
MCF-7 cell proliferation assays (Plísková et al. 
2005) and to decrease ER-mediated activity 
in ER-CALUX bioassays (Oh et al. 2007). 
Thus, the actions of non-dioxin-like PCBs 
on ER pathways are complex and depend on 
the ER subtypes that are being activated or 
antagonized. Moreover, the non-genomic ER 
pathways should also be considered. In MCF-7 
cells, PCB-153 induces the mitogen-activated 
protein kinase involved in the extracellular 
signal-regulated kinase (ERK) 1/2 signaling 
pathways (Radice et al. 2008). Several isothio-
cyanates from cruciferous vegetables and poly-
phenols from green or black tea inhibit human 
PCa cell proliferation (Gupta et al. 2001; 
Melchini et al. 2013). Interestingly, the anti-
proliferative effects of these substances seem 
to be mediated by ERK 1/2 phosphorylation 
(Melchini et al. 2013; Siddiqui et al. 2004). 
In summary, the modes of action of 
DDE and non-dioxin-like PCBs need to be 
investigated, particularly as involves all the 
various steroid receptor pathways to improve 
our understanding of their involvement in the 
proliferation or inhibition of PCa cells.
More than 20 years after the endocrine 
disruption concept first emerged (Colborn 
et al. 1993), this issue is still the subject 
of debate (Bergman et al. 2013; Dietrich 
et al. 2013; Gore et al. 2013). For instance, 
it has been reported that some EDCs have 
unexpected and potent effects at very low 
doses and/or do not generate the standard 
monotonic dose response curves seen for 
other types of compounds (Fagin 2012). 
Whether the interplay between different 
receptor mechanisms can generate unusual 
dose–response relationships and/or explains 
the associations we estimated for PCB-153 
remains to be elucidated.
Caution is required in the interpretation of 
our findings. The possibility that our findings 
were confounded by unmeasured exposures 
or could be explained by reverse causality 
cannot be excluded. However, the possible 
influence, if any, of PCa on organochlorine 
concentrations in blood remains to be studied, 
and nothing is known about any underlying 
mechanism. Also, we cannot exclude the 
possibility that our findings, particularly for 
PCBs, may have resulted from selection bias 
associated with uncontrolled or unmeasured 
common causes of competing outcomes of 
PCB-related diseases and PCa (Thompson 
et al. 2013).
Conclusions
In our study population of men of African 
descent from the French West Indies, DDE 
exposure was positively associated with PCa, 
whereas PCB-153 exposure was negatively 
associated with PCa. PCB-153 exposure was 
also inversely associated with less aggressive 
forms of the disease. These contrasting asso-
ciations may be related to the different and 
sometimes multiple modes of hormonal action 
attributed to these two classes of pollutants. 
Our findings add complexity to the already 
controversial issue of EDCs and their 
suspected effects on human health. Replication 
of these observations in other populations, as 
well as mechanistic studies, is needed before 
any causal link can be established.
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